Jim Cramer Defends Eli Lilly and Company (LLY) Amid Concerns Over Drug Adherence, Cites Long-Term Health Potential
We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...
Novo Nordisk's SWOT analysis: stock outlook amid GLP-1 market growth
A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...
STAT9h
Pharmalittle: We’re reading about the RFK Jr. confirmation hearings, CMS plans for drug-pricing talks, and more
In his first confirmation hearing, Robert F. Kennedy Jr. tried to distance himself from his past statements on abortion and ...
Investors Chronicle7h
A pharma stock emerging from Novo Nordisk's shadow
Luckily, the hiring process proceeded smoothly and Charles van Zyl joined as chief executive from Belgian pharma company UCB (BE:UCB) in 2023, while Joerg Hornstein has been in post as chief finance ...
Correction to UPS Sees 2025 Revenue Slipping Article
UPS said it had reached an agreement in principle with its top customer to lower volume by more than 50% by the second half of 2026. "UPS Sees 2025 Revenue Slipping, Plans to Cut Volumes with Top ...